NFKB1 and ovarian carcinoma: Similarly, inhibitionof NF-κB translocation or activation increased the efficacy of cisplatin on an in vivo model of ovarian cancer [21] and on cultured headand neck [36], prostate [37], and esophageal [38] cancer cell lines.In this regard, it is noteworthy that patients with esophageal tumors resistantto chemotherapy fail to downregulate NF-κB after therapy [39].